ABSTRACT
Aspergillus lacticoffeatus WU-2020 is a citric acid hyperproducer that is suitable for solid culture. Here, we present a high-quality draft of its genome sequence (35.9 Mb), which consists of 11 scaffolds and contains 11,490 genes. We also present the mitochondrial genome, which is 31.3 kb in length.
ABSTRACT
Prolyl-tRNA synthetase (PRS) is a clinically validated antimalarial target. Screening of a set of PRS ATP-site binders, initially designed for human indications, led to identification of 1-(pyridin-4-yl)pyrrolidin-2-one derivatives representing a novel antimalarial scaffold. Evidence designates cytoplasmic PRS as the drug target. The frontrunner 1 and its active enantiomer 1-S exhibited low-double-digit nanomolar activity against resistant Plasmodium falciparum (Pf) laboratory strains and development of liver schizonts. No cross-resistance with strains resistant to other known antimalarials was noted. In addition, a similar level of growth inhibition was observed against clinical field isolates of Pf and P. vivax. The slow killing profile and the relative high propensity to develop resistance in vitro (minimum inoculum resistance of 8 × 105 parasites at a selection pressure of 3 × IC50) constitute unfavorable features for treatment of malaria. However, potent blood stage and antischizontal activity are compelling for causal prophylaxis which does not require fast onset of action. Achieving sufficient on-target selectivity appears to be particularly challenging and should be the primary focus during the next steps of optimization of this chemical series. Encouraging preliminary off-target profile and oral efficacy in a humanized murine model of Pf malaria allowed us to conclude that 1-(pyridin-4-yl)pyrrolidin-2-one derivatives represent a promising starting point for the identification of novel antimalarial prophylactic agents that selectively target Plasmodium PRS.
Subject(s)
Amino Acyl-tRNA Synthetases , Antimalarials , Malaria, Falciparum , Malaria , Animals , Antimalarials/pharmacology , Humans , Malaria/drug therapy , Malaria, Falciparum/drug therapy , Mice , Plasmodium falciparumABSTRACT
Retinoic-acid-related orphan receptor γt (RORγt) inverse agonists could be used for the treatment of autoimmune diseases. Previously, we reported a novel quinazolinedione 1 a with a flexible linear linker as a novel RORγt inverse agonist. A U-shaped conformation in the complex structure of 1 a with RORγt protein was confirmed. Further improvement of the pharmacokinetic (PK) profiles was required because of the low drug exposure in mice upon oral administration (mouse AUC of 1 a: 27â ng â h â mL-1 at 1â mg â kg-1 , p.o.). To improve the PK profiles, conformationally constrained U-shaped scaffolds were investigated. As a result, morpholine analogues with improved PK profiles and high potency were successfully identified. The substituent at the N1 position of the quinazoline moiety was also modified, leading to an enhancement of reporter activity. Consequently, compound 43 (N2 -(3-chloro-4-cyanophenyl)-N4 -(3-(cyclopropylmethyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)morpholine-2,4-dicarboxamide) exhibited improved drug exposure (mouse AUC: 1289â ng â h â mL-1 at 1â mg â kg-1 , p.o.). In addition, suppression of IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model was observed for 43. The conformation of 43 with RORγt protein was also confirmed as U-shape by X-ray co-crystal structure analysis. The key interaction that boosts potency is also discussed.
Subject(s)
Cyclopentanes/pharmacology , Drug Design , Furans/pharmacology , Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Administration, Oral , Animals , Crystallography, X-Ray , Cyclopentanes/administration & dosage , Cyclopentanes/chemical synthesis , Fluorescence Resonance Energy Transfer , Furans/administration & dosage , Furans/chemical synthesis , Mice , Models, Molecular , Molecular Conformation , Nuclear Receptor Subfamily 1, Group F, Member 3/metabolismABSTRACT
We investigated the potency of TAK-828F, a RORγt inverse agonist, in murine experimental autoimmune encephalomyelitis (EAE) model. TAK-828F inhibited the differentiation of Th17 and Th1/17 cells in inguinal lymph node. Increase of these cells in central nervous system (CNS) was also inhibited by TAK-828F. Prophylactic and therapeutic treatments of TAK-828F were efficacious in the model. Plasma concentration of TAK-828F was higher than that in CNS. These results indicate that TAK-828F mainly acts at peripheral and results in the reduction of Th17- and Th1/17-dependent inflammation in CNS. Blocking RORγt may be a promising strategy for treatment of multiple sclerosis.
Subject(s)
Acetates/pharmacology , Encephalomyelitis, Autoimmune, Experimental/immunology , Naphthyridines/pharmacology , Nuclear Receptor Subfamily 1, Group F, Member 3/antagonists & inhibitors , Animals , Cell Differentiation/drug effects , Female , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Th1 Cells/drug effects , Th1 Cells/immunology , Th17 Cells/drug effects , Th17 Cells/immunologyABSTRACT
OBJECTIVE AND DESIGN: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. METHODS AND RESULTS: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ-/- mice. TAK-828F strongly inhibited IL-17 gene expression with IC50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. CONCLUSIONS: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.
Subject(s)
Acetates/pharmacology , Acetates/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Leukocytes, Mononuclear/drug effects , Naphthyridines/pharmacology , Naphthyridines/therapeutic use , Nuclear Receptor Subfamily 1, Group F, Member 3/immunology , Adolescent , Adult , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Cells, Cultured , Colon/drug effects , Colon/immunology , Colon/pathology , Disease Models, Animal , Female , Humans , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/immunology , Interleukin-17/antagonists & inhibitors , Interleukin-17/genetics , Interleukin-17/immunology , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Leukocytes, Mononuclear/immunology , Male , Mice, Inbred BALB C , Mice, Knockout , Mice, SCID , Middle Aged , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Young AdultABSTRACT
IL-17-producing Th17 cells and IFN-γ and IL-17 double-producing Th1/17 cells have been identified as the pathogenic cells in inflammatory bowel disease (IBD). Retinoic acid-related orphan receptor γt (RORγt) is a master regulator for the differentiation and activation of Th17 and Th1/17 cells. We discovered a novel orally available TAK-828F, a strong and selective RORγt inverse agonist. To assess the potential of RORγt blockade in the therapy for IBD, the efficacy of TAK-828F in activated T cell transfer mouse colitis model was investigated. This model was highly sensitive to the prophylactic treatment of anti-TNF-α monoclonal antibody but partially susceptible to sulfasalazine, tacrolimus, and prednisolone. Oral administration of TAK-828F, at doses of 1 and 3 mg/kg, b.i.d, strongly protected the progression of colitis. TAK-828F decreased the population of Th17 and Th1/17 cells in a dose-dependent manner in the mesenteric lymph node. Moreover, expression of mRNA that are characteristic of the Th17 signature, such as IL-17A and IL-17F in the colon, were inhibited by TAK-828F, while the expression of IL-10, an anti-inflammatory cytokine, was increased. In the therapeutic treatment, TAK-828F lessened disease severity compared to the vehicle control mice. Interestingly, gene expression of zonula occludens-1 (ZO-1) and mucin 2 (Muc2), which play an important role in barrier function of the intestinal mucosa, was recovered by TAK-828F. These results indicate that blocking RORγt has promising pharmacological profile in the colitis model. RORγt blockade may provide a novel therapeutic paradigm for treatment of IBD with unique mechanism by which improves imbalance of the immune system.
Subject(s)
Acetates/pharmacology , Colitis/drug therapy , Drug Inverse Agonism , Naphthyridines/pharmacology , Nuclear Receptor Subfamily 1, Group F, Member 3/antagonists & inhibitors , Animals , Cell Differentiation , Disease Models, Animal , Intestinal Mucosa/metabolism , Lymph Nodes/cytology , Mice , Th17 Cells/cytology , Th17 Cells/drug effectsABSTRACT
A series of tetrahydronaphthyridine derivatives as novel RORγt inverse agonists were designed and synthesized. We reduced the lipophilicity of tetrahydroisoquinoline compound 1 by replacement of the trimethylsilyl group and SBDD-guided scaffold exchange, which successfully afforded compound 7 with a lower log D value and tolerable in vitro activity. Consideration of LLE values in the subsequent optimization of the carboxylate tether led to the discovery of [ cis-3-({(5 R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic acid, TAK-828F (10), which showed potent RORγt inverse agonistic activity, excellent selectivity against other ROR isoforms and nuclear receptors, and a good pharmacokinetic profile. In animal studies, oral administration of compound 10 exhibited robust and dose-dependent inhibition of IL-17A cytokine expression in a mouse IL23-induced gene expression assay. Furthermore, development of clinical symptoms in a mouse experimental autoimmune encephalomyelitis model was significantly reduced. Compound 10 was selected as a clinical compound for the treatment of Th17-driven autoimmune diseases.
Subject(s)
Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Receptors, Retinoic Acid/agonists , Animals , Autoimmune Diseases/drug therapy , Drug Discovery , Drug Inverse Agonism , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Gene Expression/drug effects , Genes, Reporter/drug effects , Interleukin-17/genetics , Interleukin-17/metabolism , Interleukin-23 Subunit p19/genetics , Interleukin-23 Subunit p19/metabolism , Mice , Mice, Inbred C57BL , Models, Molecular , Molecular Structure , Structure-Activity Relationship , Th17 Cells/immunologyABSTRACT
Two incubation experiments were conducted under controlled moisture and temperature conditions to determine the effects of soil amendment treatments based on pruning waste biochar and oyster shell, on N2O and CO2 emissions from an orchard soil. In experiment 1, four treatments were tested including, control (CK), pruning waste biochar at 2% (B2%), at 10% (B10%), and oyster shell (OS), mixed with soil from two different depths, namely, from the 0-5 cm and the 0-10 cm layers. In experiment 2, only the 0-10 cm soil layer was used to study the effect of surface application of pruning waste biochar (B2% and B10%) on soil N2O and CO2 emissions. The results showed that soil pH, total C and C: N ratio increased with biochar amendment treatments. Significant reduction in soil NO3- content was observed for the B10% treatment. Although OS application increased soil pH, no effect was observed on soil mineral N content, total C or C: N ratio. The rate of N2O emissions from the 0-5 cm soil layer after B2% and B10% addition, significantly declined by 12.5% and 26.3%, respectively. However, only the B10% treatment caused significant reduction in N2O emissions from the 0-10 cm soil layer and from surface soil, by 15.1% and 13.8%, respectively. Oyster shell application had no effect on either soil N2O or CO2 emissions from either soil layer tested. Our results suggest that the addition of pruning waste biochar at a high rate has the potential to mitigate N2O emissions from orchard soils; while, oyster shell can be used for liming without altering soil N2O nor CO2 emissions.
ABSTRACT
A laboratory study was conducted to study the effects of liming and different biochar amendments on N2O and CO2 emissions from acidic tea field soil. The first experiment was done with three different rates of N treatment; N 300 (300 kg N ha-1), N 600 (600 kg N ha-1) and N 900 (900 kg N ha-1) and four different rates of bamboo biochar amendment; 0%, 0.5%, 1% and 2% biochar. The second experiment was done with three different biochars at a rate of 2% (rice husk, sawdust, and bamboo) and a control and lime treatment (dolomite) and control at two moisture levels (50% and 90% water filled pore space (WFPS)). The results showed that dolomite and biochar amendment significantly increased soil pH. However, only biochar amendment showed a significant increase in total carbon (C), C/N (the ratio of total carbon and total nitrogen), and C/IN ratio (the ratio of total carbon and inorganic nitrogen) at the end of incubation. Reduction in soil NO3--N concentration was observed under different biochar amendments. Bamboo biochar with the rates of 0.5, 1 and 2% reduced cumulative N2O emission by 38%, 48% and 61%, respectively, compare to the control soil in experiment 1. Dolomite and biochar, either alone or combined significantly reduced cumulative N2O emission by 4.6% to 32.7% in experiment 2. Reduction in N2O production under biochar amendment was due to increases in soil pH and decreases in the magnitude of mineral-N in soil. Although, both dolomite and biochar increased cumulative CO2 emission, only biochar amendment had a significant effect. The present study suggests that application of dolomite and biochar to acidic tea field soil can mitigate N2O emissions.
Subject(s)
Calcium Carbonate/chemistry , Charcoal/chemistry , Magnesium/chemistry , Nitrous Oxide/chemistry , Soil/chemistry , Acids/chemistryABSTRACT
Retinoic acid-related orphan receptor γt (RORγt) is a key master regulator of the differentiation and activation of IL-17 producing CD4+ Th17, CD8+ Tc17 and IL-17/IFN-γ co-producing cells (Th1/17 cells). These cells play critical roles in the pathogenesis of autoimmune diseases such as inflammatory bowel disease and multiple sclerosis. Thus, RORγt is an attractive target for the treatment of these diseases. We discovered TAK-828F, an orally available potent and selective RORγt inverse agonist. The inhibitory effect on the activation and differentiation of Th17 cells by TAK-828F was evaluated in mouse and human primary cells. TAK-828F inhibited IL-17 production from mouse splenocytes and human peripheral blood mononuclear cells dose-dependently at concentrations of 0.01-10⯵M without affecting the production of IFN-γ. Additionally, TAK-828F strongly inhibited Th17, Tc17 and Th1/17 cells' differentiation from naive T cells and memory CD4+ T cells at 100â¯nM without affecting Th1 cells' differentiation. In addition, TAK-828F improved Th17/Treg cells' population ratio by inhibiting Th17 cells' differentiation and up-regulating Treg cells. Furthermore, TAK-828F, at 100â¯nM, reduced the production of Th17-related cytokines (IL-17, IL-17F and IL-22) without affecting IFN-γ production in whole blood. These results demonstrate that TAK-828F has the potent and selective inhibitory activity against RORγt both in mouse and human cells. Additionally, oral administration of TAK-828F showed promising efficacy in naive T cell transfer mouse colitis model. TAK-828F may provide a novel therapeutic option to treat immune diseases by inhibiting Th17 and Th1/17 cells' differentiation and improving imbalance between Th17 and Treg cells.
Subject(s)
Drug Inverse Agonism , Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Nuclear Receptor Subfamily 1, Group F, Member 3/physiology , Administration, Oral , Animals , Cells, Cultured , Dose-Response Relationship, Drug , Female , Humans , Interleukin-17/antagonists & inhibitors , Interleukin-17/physiology , Lipopolysaccharide Receptors/antagonists & inhibitors , Lipopolysaccharide Receptors/physiology , Mice , Mice, Inbred BALB C , Mice, SCID , Th17 Cells/drug effects , Th17 Cells/physiologyABSTRACT
A series of tetrahydroisoquinoline derivatives were designed, synthesized, and evaluated for their potential as novel orally efficacious retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of Th17-driven autoimmune diseases. We carried out cyclization of the phenylglycinamide core by structure-based drug design and successfully identified a tetrahydroisoquinoline carboxylic acid derivative 14 with good biochemical binding and cellular reporter activity. Interestingly, the combination of a carboxylic acid tether and a central fused bicyclic ring was crucial for optimizing PK properties, and the compound 14 showed significantly improved PK profile. Successive optimization of the carboxylate tether led to the discovery of compound 15 with increased inverse agonistic activity and an excellent PK profile. Oral treatment of mice with compound 15 robustly and dose-dependently inhibited IL-17A production in an IL23-induced gene expression assay.
Subject(s)
Drug Discovery , Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Tetrahydroisoquinolines/pharmacology , Administration, Oral , Animals , Crystallography, X-Ray , Cytokines/biosynthesis , Dose-Response Relationship, Drug , Humans , Injections, Intradermal , Interleukin-23/administration & dosage , Interleukin-23/pharmacology , Jurkat Cells , Male , Mice , Mice, Inbred BALB C , Models, Animal , Models, Molecular , Molecular Structure , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Structure-Activity Relationship , Tetrahydroisoquinolines/administration & dosage , Tetrahydroisoquinolines/chemistryABSTRACT
A series of novel phenylglycinamides as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists were discovered through optimization of a high-throughput screen hit 1. (R)-N-(2-((3,5-Difluoro-4-(trimethylsilyl)phenyl) amino)-1-(4-methoxyphenyl)-2-oxoethyl)-3-hydroxy-N-methylisoxazole-5-carboxamide (22) was identified as one of the best of these compounds. It displayed higher subtype selectivity and specificity over other nuclear receptors and demonstrated in vivo potency to suppress the transcriptional activity of RORγt in a mouse PD (pharmacodynamic) model upon oral administration.
Subject(s)
Drug Discovery , Glycine/analogs & derivatives , Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Administration, Oral , Animals , Crystallography, X-Ray , Dose-Response Relationship, Drug , Glycine/administration & dosage , Glycine/chemistry , Glycine/pharmacology , Humans , Jurkat Cells , Male , Mice , Mice, Inbred BALB C , Models, Animal , Models, Molecular , Molecular Structure , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Structure-Activity RelationshipABSTRACT
Scleroderma has clinical characteristics including skin and other tissue fibrosis, but there is an unmet need for anti-fibrotic therapy. Halofuginone (HF) is a well-known anti-fibrosis agent in preclinical and clinical studies which exerts its effect via inhibition of TGF-ß/Smad3 signaling pathway. Recently, prolyl-tRNA synthetase (PRS) was elucidated as a target protein for HF that binds to the proline binding site of the catalytic domain of PRS. Here, we characterized a new class of PRS inhibitor (T-3833261) that is carefully designed in a way that binds to the ATP site of the catalytic domain and does not disrupt binding of proline. The anti-fibrotic activity and the mechanism of action for T-3833261 on TGF-ß-induced fibrotic assay were compared with those of HF in primary human skin fibroblast. We evaluated in vivo effect of topical application of T-3833261 and HF on TGF-ß-induced fibrotic genes expression in mice. We found that T-3833261 suppressed TGF-ß-induced α-smooth muscle actin (α-SMA) and type I collagen α1 (COL1A1) expression through the Smad3 axis in a similar fashion to HF. In vivo topical application of T-3833261 reduced the increase of fibrotic genes expression such as α-Sma, Col1a1 and Col1a2 by TGF-ß intradermal injection to the ear of a mouse. We revealed that T-3833261 is more effective than HF under the conditions of high proline concentration, as reported in fibrotic tissues. These results suggest the potential of ATP competitive PRS inhibitors for the treatment of fibrotic diseases such as scleroderma.
Subject(s)
Amino Acyl-tRNA Synthetases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Scleroderma, Systemic/drug therapy , Animals , Cells, Cultured , Drug Discovery , Enzyme Inhibitors/therapeutic use , Humans , Male , Mice , Mice, Inbred C3HABSTRACT
Previous studies have demonstrated that tocotrienol (T3) has antiatherogenic effects. However, the T3 preparations used in those studies contained considerable amounts of tocopherol (Toc), which might affect the biological activity of T3. There is little information on the effect of highly purified T3 on atherosclerosis formation. This study investigated the effect of high-purity T3 on atherosclerotic lesion formation and the underlying mechanisms. Male apolipoprotein E knockout (apoE-KO) mice were fed a cholesterol-containing diet either alone or supplemented with T3 concentrate (Toc-free T3) or with α-Toc for 12 weeks. ApoE-KO mice fed the 0.2% T3-supplemented diet showed reduced atherosclerotic lesion formation in the aortic root. The 0.2% T3 diet induced Slc27a1 and Ldlr gene expression levels in the liver, whereas the α-Toc-supplemented diet did not affect those expression levels. T3 was predominantly deposited in fat tissue in the T3 diet-fed mice, whereas α-Toc was preferentially accumulated in liver in the α-Toc diet-fed mice. Considered together, these data demonstrate that dietary T3 exerts anti-atherosclerotic effect in apoE-KO mice. The characteristic tissue distribution and biological effects of T3, that are substantially different from those of Toc, may contribute to the antiatherogenic properties of T3.
Subject(s)
Diet, High-Fat/adverse effects , Plaque, Atherosclerotic/drug therapy , Tocotrienols/pharmacology , Animals , Apolipoproteins E/genetics , Blood Glucose/metabolism , Body Weight/drug effects , Gene Expression Regulation/drug effects , Lipids/blood , Liver/drug effects , Liver/physiology , Male , Mice, Knockout , Plaque, Atherosclerotic/etiology , Plaque, Atherosclerotic/genetics , Sucrose/adverse effects , Vitamin E/blood , Vitamin E/metabolismABSTRACT
Previous studies demonstrated the ability of tocotrienol (T3) to lower levels of lipids, including cholesterol (Cho) and triglycerides (TG). Although α-tocopherol (α-Toc) reportedly inhibits the hypocholesterolemic effect of T3, there is no information about whether α-Toc influences the TG-lowering effect of T3 in vivo. In this study, we investigated the influence of α-Toc on the antihyperlipidemic effects (Cho- and TG-lowering) of rice bran tocotrienols (RBT3) in F344 rats fed a western diet. α-Toc attenuated both the Cho- and TG-lowering effects of RBT3 in vivo, whereas α-Toc alone exhibited no hypolipidemic effects. RBT3-induced Cpt-1a and Cyp7a1 gene expression was reduced by α-Toc. Furthermore, coadministration of α-Toc decreased liver and adipose tissue concentrations of tocotrienols in F344 rats. These results indicate that α-Toc has almost no antihyperlipidemic effect in vivo, but abrogates the antihyperlipidemic effect of RBT3 by reducing tissue concentrations of tocotrienols and regulating expression of genes involved in lipid metabolism. Understanding the underlying mechanism of the beneficial effects of T3 on lipid metabolism and the interaction with α-Toc will be important for developing T3-based therapeutics.
Subject(s)
Cholesterol/metabolism , Dyslipidemias/drug therapy , Oryza/chemistry , Plant Extracts/administration & dosage , Tocotrienols/administration & dosage , Triglycerides/metabolism , alpha-Tocopherol/administration & dosage , Adipose Tissue/metabolism , Animals , Carnitine O-Palmitoyltransferase/genetics , Carnitine O-Palmitoyltransferase/metabolism , Diet, Western/adverse effects , Dyslipidemias/metabolism , Humans , Liver/metabolism , Male , Rats , Rats, Inbred F344ABSTRACT
In spite of numerous advantages, transdermal drug delivery systems are unfeasible for most drugs because of the barrier effect of the stratum corneum. Ionic liquids were recently used to enhance transdermal drug delivery by improving drug solubility. In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co., Ltd., 2009). The mechanism of skin permeability enhancement by ionic liquids was investigated by hydrophilic phenol red and hydrophobic tulobuterol. Further, the skin permeation enhancing effect was remarkably superior in the acid excess state rather than the neutralization state. Infrared absorption spectrum analysis confirmed that ionic liquids/aliphatic carboxylic acid/aliphatic amine are coexisting at all mixing states. In the acid excess state, ionic liquids interact with aliphatic carboxylic acids via hydrogen bonds. Thus, the skin permeation enhancing effect is not caused by the ionic liquid alone. The "liquid salt mixture," referred to as a complex of ingredients coexisting with ionic liquids, forms a molecular assembly incorporating hydrophilic drug. This molecular assembly was considered an effective and safety enhancer of transdermal drug permeation.
Subject(s)
Caprylates/administration & dosage , Ionic Liquids/administration & dosage , Phenolsulfonphthalein/administration & dosage , Propanolamines/administration & dosage , Terbutaline/analogs & derivatives , Administration, Cutaneous , Animals , Caprylates/chemistry , Caprylates/pharmacokinetics , Ionic Liquids/chemistry , Ionic Liquids/pharmacokinetics , Male , Phenolsulfonphthalein/chemistry , Phenolsulfonphthalein/pharmacokinetics , Propanolamines/chemistry , Propanolamines/pharmacokinetics , Rats, Wistar , Skin/drug effects , Skin/metabolism , Skin Absorption/drug effects , Stearic Acids/administration & dosage , Stearic Acids/chemistry , Stearic Acids/pharmacokinetics , Terbutaline/administration & dosage , Terbutaline/chemistry , Terbutaline/pharmacokineticsABSTRACT
Tocotrienols, unsaturated forms of vitamin E, inhibit the proliferation of a variety of cancer cells and suppress angiogenesis. However, the mechanisms underlying those effects on cancer cell growth remain unclear especially under hypoxic conditions. In this study, we demonstrated that δ-tocotrienol (δ-T3) could be used as a novel anticancer agent against human colorectal adenocarcinoma (DLD-1) cells under both normoxic and hypoxic conditions. δ-T3 inhibited the growth of DLD-1 cells in a dose-dependent fashion by inducing cell cycle arrest and apoptosis. This effect was more potent under hypoxic than normoxic conditions. The anticancer effect of δ-T3 was achieved by its up-regulation of cyclin-dependent kinase inhibitors (p21 and p27), the activation of caspases and the suppression of phosphorylation of protein kinase B (Akt) at Thr(308) and Ser(473). In in vivo studies, oral administration of rice bran tocotrienol (RBT3, mainly γ-T3) (10 mg/mouse/day) significantly inhibited tumor growth in nude mice. In tumor analyses, RBT3 activated p21, p27, caspase-3 and caspase-9 and decreased Akt phosphorylation. Furthermore, immunostaining revealed that RBT3 decreased the number of cells positive for CD31/platelet endothelial cell adhesion molecule-1 in microvessels in the tumor. Taken together, these data suggest that tocotrienols are potent antitumor agents capable of inducing apoptosis and inhibiting angiogenesis under both hypoxic and normoxic conditions. Tocotrienols could have significant therapeutic potential in the clinical treatment of tumors.
Subject(s)
Colorectal Neoplasms/drug therapy , Vitamin E/analogs & derivatives , Angiogenesis Inhibitors/pharmacology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Caspase 3/genetics , Caspase 3/metabolism , Caspase 9/genetics , Caspase 9/metabolism , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Cyclin-Dependent Kinase Inhibitor p27/genetics , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Cyclin-Dependent Kinases/genetics , Cyclin-Dependent Kinases/metabolism , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Phosphorylation , Up-Regulation , Vitamin E/pharmacologyABSTRACT
Recently, tocotrienol (T3), a less well-known form of vitamin E, has gained attention as a potent hypocholesterolemic, anticancer and antiangiogenic agent. However, tocopherol (Toc), a commonly consumed form of vitamin E, has been reported to inhibit T3's effects (hypocholesterolemic and anticancer activity). There has been no report on Toc's effect on the antiangiogenic action of T3 during cotreatment. The aim of this study is to determine if and to what extent Toc affects the antiangiogenic effects of δ-T3 (the most potent isomer). This was achieved through cotreatment of human umbilical vein endothelial cells (HUVECs) with δ-T3 and Toc (α-, ß-, γ- and δ-isomers). Toc, especially α-Toc, attenuated δ-T3-induced cytotoxicity and tube degradation in cotreated HUVECs, while α-Toc treatments did not exhibit any effects. A rat aortic ring assay also showed inhibition of δ-T3's antiangiogenic effects by α-Toc. Further, in HUVEC study, cell cycle arrest and proapoptotic gene expression (p21, p27, caspase-3 and caspase-9) which were induced by δ-T3 were decreased by α-Toc treatment. α-Toc also suppressed δ-T3-induced dephosphorylation of vascular endothelial growth factor receptor 2 and Akt pathway proteins. Additionally, uptake of δ-T3 into HUVECs was decreased by α-Toc. Here we demonstrate that α-Toc not only has little antiangiogenic effect on endothelial cells but also reduces the antiangiogenic effects of δ-T3 through modulation of its cellular uptake and of relevant signal transduction pathways. Understanding T3's antiangiogenic effects and interaction with Toc is important for developing medical applications.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Vitamin E/analogs & derivatives , alpha-Tocopherol/pharmacology , Animals , Aorta/drug effects , Apoptosis/drug effects , Caspase 3/genetics , Caspase 3/metabolism , Caspase 9/genetics , Caspase 9/metabolism , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Cyclin-Dependent Kinase Inhibitor p27/genetics , Cyclin-Dependent Kinase Inhibitor p27/metabolism , In Vitro Techniques , Male , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Wistar , Signal Transduction , Tocopherols/pharmacology , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism , Vitamin E/adverse effectsABSTRACT
In the spring of 2012, a year after the Fukushima Daiichi nuclear disaster, radiocesium-contaminated Japanese cedar pollen may have caused internal exposure to the general population by inhalation. To determine if pollen had been contaminated through uptake of radiocesium by Japanese cedars and was therefore contributing to inhalation doses, the authors measured radiocesium and Japanese cedar pollen adhered to masks worn by 68 human subjects residing in eastern Japan, including Fukushima prefecture, for 8 wk in the spring of 2012. The maximum cumulative Cs and Cs radioactivities on masks worn by an individual were 21 ± 0.36 Bq and 15 ± 0.22 Bq, respectively, and the estimated effective dose during the 8 wk was 0.494 µSv. The average estimated effective dose during the 8 wk was 0.149 µSv in Fukushima prefecture and 0.015 µSv in other prefectures, including Tokyo metropolitan. The correlation between radiocesium activity and the Japanese cedar pollen count was moderate. However, imaging-plate and light microscopy observations showed that the main source of radiocesium adhered to masks was fugitive dust.
Subject(s)
Cesium Radioisotopes/analysis , Cryptomeria/chemistry , Environmental Exposure/analysis , Masks , Pollen/chemistry , Adhesiveness , Adult , Cities , Dust/analysis , Female , Fukushima Nuclear Accident , Humans , Inhalation , Male , Middle Aged , Radiation Dosage , Time Factors , Young AdultABSTRACT
The application of char to agricultural land is recognized as a potential way to sequester atmospheric carbon (C) assimilated by plants in soil, thus decelerating global warming. Such a process would also be expected to improve plant growth and the physical and chemical properties of soil. However, field investigations of the effects of continuous char application have not been reported. In the present study, the effects of repetitive bamboo char application on CO2, CH4, and N2O flux from soil, soil C content, and crop yield were investigated at two upland fields over five crop seasons. Three treatments: chemical fertilizer (CF) applied plots (Control plot); cattle manure (CM) (10 t ha(-1)) and CF applied plot (CM plot); and bamboo char (20 t ha(-1)), cattle manure (10 t ha(-1)), and CF applied plot (Char/CM plot), were arranged in each field. After three crop seasons, the fourth treatment with char was applied without CF (Char plot) was given to one of the fields. CM and/or char were applied every crop season. Gas fluxes were measured using the static chamber method. Seasonal variations in CO2 flux and total CO2 emissions were consistently similar between the CM and Char/CM plots and between the Char and Control plots. As such, the decomposition rate of bamboo char was quite small, and the positive or negative effect of char on CM decomposition was not significant in the fields. Soil C analysis provided confirmation of this. CM application enhanced N2O emission mainly in the summer crop season. The differences in total N2O emission between the Char/CM and CM plots as well as between the Char and Control plots were insignificant in most cases. Total CH4 flux was negligibly small in all cases. Although the yield of winter crop (broccoli) in the Char/CM plots was twice observed to be higher than that in the Control and CM plots at one of the fields, in general, the char application had no effect on overall crop yield. Thus, the repeated application of bamboo char had no significant influence on greenhouse gas emissions and crop yields, but a high C accumulating function was found.